Silence Therapeutics plcSLN stock score: 55/100
$19.81 · -0.05% · Scored Nov 19, 2026
- Technical
- 66
- Fundamental
- 53
- News
- 44
The reading
Silence Therapeutics (SLN) scores 55 out of 100, which reads neutral, higher than 62% of Healthcare stocks and 61% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 53, technicals 66.
Among the fundamentals, Quick Ratio at 100 and Current Ratio at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 67 and contrarian oscillators 32 — a split worth reading before trusting the technical total.
News sentiment is neutral at 44; it is shown, not counted in the composite.
Since Aug 24, 2026 the composite has ranged from 44 to 59, and it ends the period where it started.
About Silence Therapeutics
Silence Therapeutics (SLN) is a London-based biotechnology company that develops RNA interference medicines, which silence specific genes in the liver to reduce production of disease-causing proteins. Its mRNAi GOLD platform links short interfering RNA molecules to a sugar that directs them to liver cells, allowing infrequent dosing. Its most advanced candidate, zerlasiran, is designed to lower lipoprotein(a), an inherited risk factor for heart disease, and the company has completed preparations for late-stage development and is seeking a partner to fund and run it. Its second program, divesiran, targets the TMPRSS6 gene to treat polycythemia vera, a rare blood cancer, by reducing excess red blood cell production. Silence has also worked with larger drug makers under research collaborations, earning upfront payments and milestones, and it funds its own programs largely with cash raised from investors. Its shares trade in the United States as American depositary shares.
In lipoprotein(a), Silence competes with Novartis, Amgen and Eli Lilly, which have their own candidates in late-stage trials, while in polycythemia vera it faces Incyte, Takeda and Protagonist Therapeutics, and other treatments. Its edge rests on a platform that has produced durable gene silencing in clinical trials and a pipeline aimed at large cardiovascular markets and rare blood disorders. Investors who follow SLN stock tend to watch partnering of zerlasiran. Clinical data from divesiran are closely followed. Collaboration income, cash runway and leadership changes are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward SLN’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
53Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
Current assets divided by current liabilities: the ability to pay short-term bills.
How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
EV/Revenue compares the whole company's value, debt included, with its sales.
Price-to-Sales ratio compares market capitalization to annual revenue.
28 weighted scorers; 11 had no data today and are left out rather than counted as zero.
Technical · daily
63Pulling it up
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
- EMA 50100
Exponential Moving Average (50-period) is a key intermediate-term trend indicator that responds more quickly than SMA-50.
- SMA 50100
Simple Moving Average (50-period) is a widely-watched intermediate-term trend gauge.
Holding it back
Williams %R (28-period) places the close within the last 28 periods' high-low range.
Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.
Annualised volatility of the last 60 daily returns.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 44
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 49 | 1 |
| Daily | 63 | 3 |
| Weekly | 70 | 2 |
| Monthly | 75 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 20, 2026 | 55 |
| Nov 19, 2026 | 56 |
| Nov 18, 2026 | 56 |
| Nov 16, 2026 | 55 |
| Nov 15, 2026 | 55 |
| Nov 14, 2026 | 55 |
| Nov 13, 2026 | 59 |
| Nov 12, 2026 | 56 |
| Nov 11, 2026 | 56 |
| Nov 8, 2026 | 55 |
| Nov 7, 2026 | 55 |
| Nov 6, 2026 | 54 |
| Nov 5, 2026 | 57 |
| Nov 4, 2026 | 56 |
| Nov 3, 2026 | 56 |
| Nov 2, 2026 | 56 |
| Oct 31, 2026 | 56 |
| Oct 30, 2026 | 57 |
| Oct 29, 2026 | 57 |
| Oct 28, 2026 | 57 |
| Oct 27, 2026 | 57 |
| Oct 26, 2026 | 57 |
| Oct 25, 2026 | 57 |
| Oct 24, 2026 | 57 |
| Oct 23, 2026 | 57 |
| Oct 22, 2026 | 57 |
| Oct 21, 2026 | 59 |
| Oct 20, 2026 | 59 |
| Oct 19, 2026 | 44 |
| Oct 18, 2026 | 44 |
| Oct 17, 2026 | 44 |
| Oct 16, 2026 | 46 |
| Oct 15, 2026 | 45 |
| Oct 14, 2026 | 45 |
| Oct 13, 2026 | 48 |
| Oct 12, 2026 | 48 |
| Oct 11, 2026 | 48 |
| Oct 10, 2026 | 48 |
| Oct 9, 2026 | 47 |
| Oct 8, 2026 | 48 |
| Oct 7, 2026 | 47 |
| Oct 6, 2026 | 48 |
| Oct 5, 2026 | 50 |
| Oct 4, 2026 | 50 |
| Oct 3, 2026 | 50 |
| Oct 2, 2026 | 50 |
| Oct 1, 2026 | 52 |
| Sep 30, 2026 | 51 |
| Sep 29, 2026 | 52 |
| Sep 28, 2026 | 52 |
| Sep 27, 2026 | 52 |
| Sep 26, 2026 | 51 |
| Sep 25, 2026 | 52 |
| Sep 24, 2026 | 54 |
| Sep 23, 2026 | 53 |
| Sep 22, 2026 | 53 |
| Sep 21, 2026 | 53 |
| Sep 20, 2026 | 53 |
| Sep 19, 2026 | 52 |
| Sep 18, 2026 | 54 |
| Sep 17, 2026 | 53 |
| Sep 16, 2026 | 53 |
| Sep 15, 2026 | 54 |
| Sep 14, 2026 | 54 |
| Sep 13, 2026 | 54 |
| Sep 12, 2026 | 54 |
| Sep 11, 2026 | 54 |
| Sep 10, 2026 | 54 |
| Sep 9, 2026 | 55 |
| Sep 8, 2026 | 55 |
| Sep 7, 2026 | 55 |
| Sep 6, 2026 | 55 |
| Sep 5, 2026 | 56 |
| Sep 4, 2026 | 57 |
| Sep 3, 2026 | 57 |
| Sep 2, 2026 | 56 |
| Sep 1, 2026 | 56 |
| Aug 31, 2026 | 55 |
| Aug 30, 2026 | 55 |
| Aug 29, 2026 | 55 |
| Aug 28, 2026 | 55 |
| Aug 27, 2026 | 56 |
| Aug 26, 2026 | 56 |
| Aug 25, 2026 | 55 |
| Aug 24, 2026 | 55 |
Key facts
- Market cap
- $1.2B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.34
- Risk grade (1–10)
- —
- Next earnings
- Nov 12, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| GHRS GH Research | $1.3B | 42 |
| NVAX Novavax | $1.3B | 55 |
| MNKD MannKind | $1.3B | 56 |
| MLYS Mineralys Therapeutics | $1.3B | 31 |
| TSHA Taysha Gene Therapies | $1.2B | 47 |
| GPCR Structure Therapeutics | $1.2B | 29 |
Questions
What is SLN's stock rating today?
SLN scores 55/100 (Neutral) as of Nov 19, 2026: technical 66, fundamental 53, and news sentiment 44, which is shown but not counted. Scores are recomputed every night.
What does Silence Therapeutics do?
Silence Therapeutics (SLN) is a London-based biotechnology company that develops RNA interference medicines, which silence specific genes in the liver to reduce production of disease-causing proteins. Its mRNAi GOLD platform links short interfering RNA molecules to a sugar that directs them to liver cells, allowing infrequent dosing.
Is SLN stock a buy?
The score is not a buy or sell recommendation. A 55 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the SLN score calculated?
89 weighted scorers feed it today: 28 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/sln/"><img src="https://stocksscores.com/stocks/sln/badge.svg" alt="SLN stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/sln/)